Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents

Published:2024-07-22 Issue:8 Volume:33 Page:839-849
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Amadeo Elisabeth¹,Foti Silvia¹,Camera Silvia¹,Rossari Federico¹²,Persano Mara³,Lo Prinzi Federica⁴,Vitiello Francesco¹,Casadei-Gardini Andrea¹,Rimini Margherita¹

Affiliation:

1. Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy

2. San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy

3. Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy

4. Operative Research Unit of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2024.2377321

Reference112 articles.

1. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma

2. Hepatocellular carcinoma

3. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma

4. Breakthroughs in Hepatocellular Carcinoma Therapies

5. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP